Sail Biomedicines

Sail Biomedicines is a private Flagship Pioneering-backed biotechnology company developing programmable RNA medicines. The company was formed in October 2023 through the combination of Laronde and Senda Biosciences and centers its platform on translatable circular RNA called Endless RNA (eRNA), targeted nanoparticles (TNPs), and proprietary AI-enabled design tools. Sail is pursuing extra-hepatic delivery and durable in vivo expression to expand the use of RNA medicines beyond conventional mRNA applications. Its disclosed pipeline includes a preclinical in vivo eRNA CAR-T candidate for autoimmune diseases and a malaria eRNA vaccine program, while the company also cites broader interest in metabolic, infectious, and rare diseases. The business is best characterized as a platform-centric RNA therapeutics company rather than a single-asset developer.